The biotech sector, proxied by the XBI ETF, is trading significantly higher today following a major positive catalyst from industry leader Moderna. The company announced that its personalized cancer vaccine, developed in partnership with Merck, met its primary endpoint in a Phase 3 trial for melanoma. This news has driven a massive rally in Moderna's stock and is lifting sentiment across the entire biotechnology industry, reinforcing investor optimism in the potential of mRNA technology and the broader drug development pipeline.